CureVac NV (CVAC)
3.89
+0.12
(+3.18%)
USD |
NASDAQ |
May 31, 16:00
3.88
-0.01
(-0.26%)
After-Hours: 20:00
CureVac Revenue (Quarterly): 13.44M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 13.44M |
| December 31, 2023 | 24.30M |
| September 30, 2023 | 17.95M |
| June 30, 2023 | 8.264M |
| March 31, 2023 | 7.657M |
| December 31, 2022 | 11.95M |
| September 30, 2022 | 11.29M |
| June 30, 2022 | 21.46M |
| March 31, 2022 | 27.35M |
| December 31, 2021 | 47.15M |
| Date | Value |
|---|---|
| September 30, 2021 | 34.59M |
| June 30, 2021 | 26.99M |
| March 31, 2021 | 12.09M |
| December 31, 2020 | 7.203M |
| September 30, 2020 | 6.036M |
| June 30, 2020 | 38.05M |
| March 31, 2020 | 3.442M |
| December 31, 2019 | 7.548M |
| September 30, 2019 | 1.219M |
| March 31, 2019 | 3.585M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.219M
Minimum
Sep 2019
47.15M
Maximum
Dec 2021
17.26M
Average
12.09M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
| BioNTech SE | 203.77M |
| Affimed NV | 0.4448M |
| InflaRx NV | 0.0391M |
| MorphoSys AG | 63.62M |
| Immatics NV | 32.88M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -76.63M |
| Total Expenses (Quarterly) | 94.08M |
| EPS Diluted (Quarterly) | -0.3367 |
| Enterprise Value | 544.31M |
| Gross Profit Margin (Quarterly) | -236.9% |
| Profit Margin (Quarterly) | -570.2% |
| Earnings Yield | -34.02% |
| Normalized Earnings Yield | -34.27 |